Sign up Australia
Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers Ltd to promote proprietary glaucoma surgery

Ellex Medical Lasers Ltd to promote proprietary glaucoma surgery

Ellex Medical Lasers Ltd (ASX:ELX) will present a positive 12-month case series data for the company’s proprietary ABiC minimally invasive glaucoma surgery (MIGS) procedure at the American Society of Cataract and Refractive Surgery meeting in New Orleans, U.S.A.

Ellex manufactures lasers and other medical devices for the diagnosis and treatment of eye disease.

The results from the case series study show that ABiC can effectively reduce intraocular pressure (IOP or fluid pressure inside the eye) and medication dependence in glaucoma patients with minimal complications.

The case series study, which was undertaken in the U.S., included 228 eyes with mild-to-moderate glaucoma who underwent ABiC either alone or in combination with cataract surgery.

Encouragingly, in 98 patients who underwent ABiC as a standalone procedure, there was an average decrease of 36.74% in IOP and 66.66% in medications.

Data for the entire patient cohort showed a total average decrease of 30% in IOP and a 50% reduction in medications, 12 months after the ABiC surgery.

The company had developed ABiC to address the shortcomings of conventional glaucoma treatment options, which includes chronic use of daily multi-dose topical glaucoma medications.

Since launching ABiC into the fast-growing MIGS market, Ellex has achieved sales growth in the U.S of 25% during the 9 months to 31 March 2016, compared with the prior corresponding period.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

Newswire
November 30 2016

Related Articles

myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use